New Drugs for Weight Loss: What Plan Sponsors Need to Know

Segal

The latest generation of prescription drugs originally developed to help people manage their type 2 diabetes, such as Ozempic^®, have been causing quite a stir for patients, health professionals and benefit plans now that some have been both approved and promoted for treating obesity. The effectiveness of and demand for these newer drugs are prompting some plan sponsors that exclude anti-obesity drugs from coverage to revisit plan rules. However, there are concerns about the potentially large target patient population, as well as the increased utilization and the high cost of these drugs.

You’re invited to join a webinar that will address the range of issues plan sponsors face related to weight-loss benefits and potential coverage of newer anti-obesity drug therapies.

You’ll gain an understanding of

• The history behind glucagon-like peptide-1 or GLP-1 medications and their on- and off-label use
• How GLP-1 medication usage trends are impacting benefit plans
• Ways to better manage the rising utilization and cost of GLP-1 medications
• How federal laws like the Mental Health Parity and Addiction Equity Act affect coverage decisions
• What to consider before deciding to cover anti-obesity medications, including the importance of incorporating behavioral health programs into your strategy

More Information, How to Register